1035. Manufacturing Processes of SER-109, a Purified Investigational Microbiome Therapeutic, Reduce Risk of Transmission of Emerging and Undetected Infections in Donor Stool

BACKGROUND: Fecal microbiota transplantation (FMT) is vulnerable to emerging pathogens due to reliance on donor screening for risk mitigation. These concerns were highlighted by dual FDA safety alerts regarding FMT transmission of bacterial pathogens, which were recognized in hindsight only after ho...

Descripción completa

Detalles Bibliográficos
Autores principales: McChalicher, Christopher, Abdulaziz, Ahmad, Halvorsen, Elizabeth, Lombardo, Mary-Jane, Winkler, Jonathan, Almomani, Sanabel, McGovern, Barbara, McKenzie, Gregory, Ege, David, Aunins, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690818/
http://dx.doi.org/10.1093/ofid/ofab466.1229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690818/
http://dx.doi.org/10.1093/ofid/ofab466.1229

Ejemplares similares